Outlook Therapeutics (OTLK) Research & Development (2015 - 2026)
Outlook Therapeutics (OTLK) reported Research & Development of $4.5 million for Q1 2026, up 2.12% year-over-year from $4.4 million in Q1 2025, and up 23.83% quarter-over-quarter from $3.6 million in Q4 2025.
Outlook Therapeutics (OTLK) Research & Development (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Research & Development data on file, last reported at $4.5 million in Q1 2026.
- Research & Development for Q1 2026 came in at $4.5 million, up 2.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.2 million (down 43.78% YoY), and the FY2025 annual result was $27.2 million, down 34.92% from the prior year.
- Research & Development improved to $4.5 million in Q1 2026 per OTLK's latest filing, from $3.6 million in the prior quarter.
- Over five years, Research & Development peaked at $13.5 million in Q1 2024 and troughed at $544948.0 in Q1 2023.
- A 5-year average of $8.0 million and a median of $9.0 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development plunged 95.54% in 2023, then jumped 2378.94% in 2024.
- A 5-year view of Research & Development shows it stood at $9.9 million in 2022, then plunged by 54.07% to $4.5 million in 2023, then surged by 113.28% to $9.7 million in 2024, then slumped by 62.38% to $3.6 million in 2025, then increased by 23.83% to $4.5 million in 2026.
- Business Quant data shows OTLK's Research & Development at $4.5 million in Q1 2026, $3.6 million in Q4 2025, and $6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -58.00 Mn |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | 4.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.50 Mn |
| Dec 31, 2025 | 3.63 Mn |
| Sep 30, 2025 | 5.98 Mn |
| Jun 30, 2025 | 7.13 Mn |
| Mar 31, 2025 | 4.41 Mn |
| Dec 31, 2024 | 9.66 Mn |
| Sep 30, 2024 | 12.52 Mn |
| Jun 30, 2024 | 11.20 Mn |
| Mar 31, 2024 | 13.51 Mn |
| Dec 31, 2023 | 4.53 Mn |
| Sep 30, 2023 | 4.94 Mn |
| Jun 30, 2023 | 11.10 Mn |
| Mar 31, 2023 | 544,948.00 |
| Dec 31, 2022 | 9.86 Mn |
| Sep 30, 2022 | 8.99 Mn |
| Jun 30, 2022 | 11.25 Mn |
| Mar 31, 2022 | 12.22 Mn |
| Dec 31, 2021 | 9.87 Mn |
| Sep 30, 2021 | 9.93 Mn |
| Jun 30, 2021 | 8.55 Mn |